Beijing SL Pharmaceutical Co., Ltd.

符号: 002038.SZ

SHZ

8.62

CNY

今天的市场价格

31.0841
市盈率
2.4867
PEG比率
8.86B
MRK市值
0.01%
DIV收益率

Beijing SL Pharmaceutical Co., Ltd. (002038-SZ) 财务报表

Q: 什么是 Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) 总资产是多少？

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) 总资产为 .

Download

年度季度

线性对数

在图表中，您可以看到的动态默认数字 Beijing SL Pharmaceutical Co., Ltd. (002038.SZ). 的默认数据。公司收入显示 781.662 M 的平均值，即 0.214 % 增长率。整个期间的平均毛利润为 586.377 M，即 0.211 %. 平均毛利率为 0.739 %. 公司去年的净收入增长率为 0.778 %，等于 0.144 % % 整个公司历史的平均增长率.,

年度季度

10Y 20Y 30Y 40Y

资产负债表

深入分析 Beijing SL Pharmaceutical Co., Ltd. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 0.068. 在流动资产领域，002038.SZ 的报告货币为2639.981. 这些资产中的很大一部分，即 2133.016 是现金和短期投资。与去年的数据相比，该部分的变化率为1.883%. 公司的长期投资虽然不是其重点，但以报告货币计算的1587.258（如果有的话）为1587.258。这表明与上一报告期相比，22.554% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 0. 这一数字表明，0.000% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 5800.616. 这方面的年同比变化率为 0.061%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为236.214，存货估值为 144.46，商誉估值为 0（如有. 无形资产总额（如果有）按 1143.67 估值.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004	2002
balance-sheet.row.cash-and-short-term-investments	5056.78	2133	739.9	990.2	837.3	1401.3	1195.9	1509.1	1208.2	1508.3	866.3	769.3	669.8	581.6	457.5	440	433	292.9	205.7	195.4	237.8	45.9	11.7	3.7
balance-sheet.row.short-term-investments	2289.51	1449.2	144.9	162.4	173.8	140.5	29.7	70.3	36.5	38.7	9.5	6.4	8.9	8.8	11.6	21.9	12.2	31	0	0	0	14	0	0
balance-sheet.row.net-receivables	1134.59	236.2	406.4	534	649.9	841.2	847.5	812.2	795	795.3	892.7	637.6	587.9	383.1	202.8	241.6	179.1	147.1	133.6	75.3	37.7	31.4	29.6	34.7
balance-sheet.row.inventory	625.05	144.5	136.8	124.8	112	108.3	251.3	275.7	198.2	129.7	112.2	110.9	57	64.6	29.5	24.4	8.6	6.1	7.5	8.2	7.7	9.2	3.9	1.1
balance-sheet.row.other-current-assets	2585.99	126.3	714.5	648.7	608.1	514.4	508.5	456	536.2	150.9	411.8	208.1	181.1	160	75.5	53	15.8	-0.1	0	14.8	0	0	-0.1	-0.1
balance-sheet.row.total-current-assets	9402.41	2640	1997.7	2297.7	2207.3	2865.3	2803.2	3053	2737.7	2584.2	2283	1725.9	1495.8	1189.2	765.3	758.9	636.5	446.1	346.8	293.6	283.2	86.5	45.2	39.3
balance-sheet.row.property-plant-equipment-net	2044.8	538.4	527.3	604	589.2	588	559.3	556.3	481.1	459.8	414.1	359.3	331.9	197.9	182.2	101.8	103.3	110.5	99.2	94.1	73.2	46.8	46.2	27.8
balance-sheet.row.goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	4425.3	1143.7	978.5	872.8	713.7	641.2	708.8	363.2	259.2	218.7	198.4	184.5	107.9	78.8	67.8	53.5	30	22.1	15.6	18.2	18.9	18.6	11.5	10.1
balance-sheet.row.goodwill-and-intangible-assets	4425.3	1143.7	978.5	872.8	713.7	641.2	708.8	363.2	259.2	218.7	198.4	184.5	107.9	78.8	67.8	53.5	30	22.1	15.6	18.2	18.9	18.6	11.5	10.1
balance-sheet.row.long-term-investments	5601.25	1587.3	1295.1	1241.3	1077.7	447.9	490.4	138.8	255.8	218.8	216	329	247.4	211.6	215	50.4	4.9	-24.1	0	0	0	0	0	0
balance-sheet.row.tax-assets	77.69	0	39.5	27.7	25.4	22.6	14.4	23.8	18	14.3	10.5	6.9	7.3	10.3	3.7	3.9	1.6	1.1	1	0	0	0	0	0
balance-sheet.row.other-non-current-assets	3192.71	368.4	1037.7	717	781.6	659.9	412.2	449.9	329.5	265.9	196.9	106.5	26.3	48.4	14.5	51.3	12.2	31	-1	0	14.4	0	0	0
balance-sheet.row.total-non-current-assets	15341.75	3637.8	3878.2	3462.7	3187.5	2359.6	2185.1	1532	1343.6	1177.5	1036	986.2	720.9	547	483.3	260.9	152	140.6	114.8	112.3	106.6	65.4	57.7	37.8
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	24744.16	6277.8	5875.8	5760.5	5394.8	5225	4988.3	4585.1	4081.3	3761.6	3319.1	2712.1	2216.7	1736.1	1248.6	1019.8	788.5	586.6	461.6	405.9	389.8	151.8	102.8	77.1
balance-sheet.row.account-payables	778.6	213.2	176.2	191.4	179.9	178.5	264.9	111.5	30.9	39.8	42.7	36.5	27.1	9.6	8.1	11.8	11.6	14.6	14.4	8.4	19.3	4.4	5.1	0.2
balance-sheet.row.short-term-debt	46.32	37.6	-27.9	0.2	5.5	3.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	19.2	0	1.5
balance-sheet.row.tax-payables	11.48	0	9	16.3	13.7	25.8	51	65.1	46.8	44.2	50.7	46.2	41.7	21.9	20.8	13.5	5.8	5.2	4.1	1.7	-0.9	-1.2	1.5	0.6
balance-sheet.row.long-term-debt-total	0	0	0	2.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Deferred Revenue Non Current	185.63	47	51.4	56.2	61	65.3	29.2	33.1	33.5	33.2	17.5	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	223.42	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	379.81	107.3	112.7	1.6	1.5	14.2	175.6	138.2	82.8	71.2	73.1	67.1	65.2	35.6	29.2	20.4	14.3	17.6	11.6	8.9	3	1.7	6.5	0
balance-sheet.row.total-non-current-liabilities	362.01	47.4	107.8	109.3	95.1	71.1	29.2	36	37.5	37.4	22.2	19.6	12.9	5.3	0	4.5	0	2.5	9.4	6.1	6.1	4.4	5.6	3.6
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	0	0	0	2.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	1621.95	420.7	396.6	434.2	410.1	403.8	469.7	285.7	151.2	148.4	137.9	123.1	105.2	50.5	37.2	36.8	25.9	34.7	35.4	23.4	28.4	36.8	17.2	10.8
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	4109.4	1027.3	1027.3	1027.3	1027.3	1027.3	684.9	684.9	684.9	684.9	456.8	456.8	380.7	380.7	253	251.4	248.4	124.2	82.8	82.8	69	50	40	40
balance-sheet.row.retained-earnings	16182.54	4077.8	3763.8	3632.1	3308.9	3184.1	3272.9	3129.9	2787.7	2518.8	2364	1826.6	1478.8	1118.5	804	602.1	426	236.4	129.4	92.4	77.5	50.2	37.7	21.3
balance-sheet.row.accumulated-other-comprehensive-income-loss	2743.99	695.1	676.5	651.9	638.2	596.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	0.86	0.4	0.4	0.1	0.1	0.1	540.1	455.8	423.9	374.1	327.1	282.2	180.6	124.7	133.8	112	86	190.7	213.3	206.7	214.9	14.7	7.9	5
balance-sheet.row.total-stockholders-equity	23036.79	5800.6	5468.1	5311.5	4974.6	4808.2	4497.8	4270.6	3896.5	3577.8	3147.9	2565.7	2040.1	1624	1190.8	965.5	760.4	551.3	425.6	381.9	361.4	115	85.6	66.3
balance-sheet.row.total-liabilities-and-stockholders-equity	24744.16	6277.8	5875.8	5760.5	5394.8	5225	4988.3	4585.1	4081.3	3761.6	3319.1	2712.1	2216.7	1736.1	1248.6	1019.8	788.5	586.6	461.6	405.9	389.8	151.8	102.8	77.1
balance-sheet.row.minority-interest	38.37	9.4	11.2	14.7	10.1	13	20.7	28.8	33.6	35.4	33.2	23.3	71.4	61.6	20.6	17.5	2.2	0.7	0.6	0.6	0.1	0.1	0	0
balance-sheet.row.total-equity	23075.16	5810	5479.2	5326.2	4984.7	4821.2	4518.5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	24744.16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	7890.75	3036.4	1440.1	1403.6	1251.5	588.4	520	209.1	292.3	257.6	225.5	335.4	256.3	220.3	226.6	72.3	17.1	6.9	0	0	0	14	0	0
balance-sheet.row.total-debt	75.19	37.6	0	2.5	5.5	3.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	19.2	0	1.5
balance-sheet.row.net-debt	-2692.08	-646.2	-595	-825.4	-658	-1256.9	-1166.2	-1438.8	-1171.7	-1469.6	-856.8	-763	-660.9	-572.8	-445.9	-418.1	-420.8	-261.9	-205.7	-195.4	-236.8	-12.7	-11.7	-2.2

现金流量表

在 Beijing SL Pharmaceutical Co., Ltd. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 0.216 的转变。该公司最近通过发行 0 扩大了股本，与上一年相比出现了-0.000 的差异. 有趣的是，公司的部分股票，特别是 0，是由公司自己回购的。这一举动导致0.000 比上一年有所变化。同时，以报告货币计算，公司的应付账款目前为 36.56. 公司的投资活动产生了现金使用净额，按报告货币计算达到-540403356.360. 与上一年相比， 1.732 发生了变化. 在同一时期，公司记录了 113.88, -22.21 和 0，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将-102.73 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 0，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln USD Growth	TTM	2021	2019	2017	2015	2013	2011	2009	2007	2005	2003
cash-flows.row.net-income	284.9	228.3	421.3	361.5	479.5	563.4	528.8	447.4	577.2	701	572	480	524.4	276.4	243.7	218.4	134.8	50.3	33.8	32	31.2
cash-flows.row.depreciation-and-amortization	6.41	113.9	99.8	89.5	76.6	55.8	37.5	33.6	32.7	30.7	22.5	20.3	17.6	13.7	12.3	11.9	9.9	7.4	10	9.1	8
cash-flows.row.deferred-income-tax	0	-6.3	14.4	25.6	-7.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	0	6.3	-14.4	-25.6	7.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	15.41	113.7	129.1	197.9	141.7	-142	30.2	-57.2	-45.1	-226.2	-213.3	-75.3	-95.9	-35.6	-66.9	-48.8	-14.3	4	6	-10.1	-9.8
cash-flows.row.account-receivables	19.66	82.9	108.6	198.8	-9.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	-4.25	0.6	-11.5	-3.7	142.9	24.4	-77.5	-68.5	-17.5	-1.3	-53.9	7.6	-35	-5.2	-15.6	-2.5	1.4	0.6	-0.5	1.5	-5.3
cash-flows.row.account-payables	0	36.6	17.5	-22.7	15.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	0	-6.3	14.4	25.6	-7.1	-166.4	107.7	11.3	-27.7	-224.9	-159.4	-82.9	-60.8	-30.4	-51.3	-46.3	-15.7	3.4	6.5	-11.6	-4.6
cash-flows.row.other-non-cash-items	269.47	-66.1	-185.6	-233.1	-31.9	7.9	-215.8	-26.9	-60	-40.6	-33.8	-26.4	-217.5	-16.4	-14.8	12.8	-42.1	-4.2	-2.4	0.3	1.2
cash-flows.row.net-cash-provided-by-operating-activities	481.62	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-213.1	-163.5	-236.9	-255.9	-272.8	-227.4	-229.6	-164.2	-129.7	-151	-109.5	-247.9	-73.1	-43	-30.5	-23.6	-26.6	-64.9	-81.2	-17.7	-16.4
cash-flows.row.acquisitions-net	0.01	-3.4	16.5	0	0	227.4	229.7	164.2	-6.8	151.3	0	0.4	0.3	0	0	23.6	27.5	64.9	81.2	0	0
cash-flows.row.purchases-of-investments	-582.01	-1247.4	-1061	-1517.2	-579.9	-987.6	-64.8	-485.4	-146.7	-210.9	-229.6	-752.1	-904.5	-142.7	-107.6	-16.8	-103.9	-196.1	-173	0	-14
cash-flows.row.sales-maturities-of-investments	487.59	896.1	1092.6	964.3	469.3	799.3	315.5	79	526.7	74.7	208.6	714.1	894.2	17	6.5	21.5	210.8	282.3	6.3	0	0
cash-flows.row.other-investing-activites	-71.42	-22.2	-9	-33.3	0.1	-227.4	-229.6	-164.2	0	-151	-19.6	37.1	0.6	4.3	-4.7	-23.6	-26.6	-64.9	-81.2	0	0
cash-flows.row.net-cash-used-for-investing-activites	-383.53	-540.4	-197.8	-842.1	-383.2	-415.7	21	-570.7	243.5	-287	-150.1	-248.4	-82.5	-164.4	-136.2	-18.9	81.1	21.2	-247.9	-17.8	-30.4
cash-flows.row.debt-repayment	0	0	-11	-5.6	-3.9	0	0	0	0	0	-0.3	-76.1	0	0	0	0	0	0	-1	-19.2	0
cash-flows.row.common-stock-issued	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	0	-102.7	-102.9	-205.8	-205.6	-342.4	-137	-137	-137	-91.4	-95.2	0	-63.2	-50.3	-49.7	-12.4	-13.2	-8.3	-13.8	-4.7	-0.2
cash-flows.row.other-financing-activites	0	0	10.6	4.5	10.5	0	2.3	12.8	14	-3.5	0.6	13.5	44	4.3	8.8	1	0	4.7	2.8	216.3	20.3
cash-flows.row.net-cash-used-provided-by-financing-activities	-110.25	-102.7	-103.3	-206.9	-199	-342.4	-134.7	-124.2	-123	-94.8	-94.9	-62.6	-19.2	-45.9	-40.9	-11.4	-13.2	-3.6	-12	192.4	20.1
cash-flows.row.effect-of-forex-changes-on-cash	0.03	0.1	0	0.1	0.2	0.3	0	0.1	-1.1	-0.9	-0.3	0.6	0	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	-153.55	-253.2	163.5	-633.1	83.9	-272.6	267.1	-297.8	624.4	82.2	102.1	88.1	126.9	27.8	-2.7	163.9	156.3	75.2	-212.4	205.9	20.2
cash-flows.row.cash-at-end-of-period	2465.46	527.2	780.4	617	1250.1	1166.2	1438.8	1171.7	1469.6	845.2	763	660.9	572.8	445.9	418.1	420.8	256.9	100.6	25.4	237.8	31.9
cash-flows.row.cash-at-beginning-of-period	2619.01	780.4	617	1250.1	1166.2	1438.8	1171.7	1469.6	845.2	763	660.9	572.8	445.9	418.1	420.8	256.9	100.6	25.4	237.8	31.9	11.7
cash-flows.row.operating-cash-flow	481.62	389.8	464.6	415.8	665.8	485.2	380.7	396.9	504.9	465	347.4	398.6	228.6	238.1	174.4	194.3	88.4	57.6	47.5	31.3	30.6
cash-flows.row.capital-expenditure	-213.1	-163.5	-236.9	-255.9	-272.8	-227.4	-229.6	-164.2	-129.7	-151	-109.5	-247.9	-73.1	-43	-30.5	-23.6	-26.6	-64.9	-81.2	-17.7	-16.4
cash-flows.row.free-cash-flow	268.53	226.3	227.7	159.9	393	257.8	151.1	232.6	375.2	314	237.9	150.7	155.5	195.1	143.9	170.7	61.8	-7.4	-33.8	13.5	14.1

利润表行

Beijing SL Pharmaceutical Co., Ltd. 的收入与上期相比变化了 -0.040%。据报告, 002038.SZ 的毛利润为 702.76。该公司的营业费用为 491.63，与上年相比变化了 -30.872%. 折旧和摊销费用为 113.88，与上一会计期间相比变化了 -0.095%. 营业费用报告为 491.63，显示-30.872% 的同比变化。销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。基于近期数据的EBITDA为 0，同比增长-0.198%. 营业收入为 211.13，与上年相比变化了-0.198%. 净利润的变化率为 0.778%。去年的净收入为416.69.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004	2002
income-statement-row.row.total-revenue	962.21	1008.3	1050.2	1214.8	1112.7	2029.7	2167.5	1242.1	1009.8	1156.5	1243	1161.8	1007	622.8	457.8	390	358	237.5	143.9	118.6	93.1	71.1	49.9	32.2
income-statement-row.row.cost-of-revenue	238.91	305.5	157	183.6	163.4	417.4	448.3	364.3	351.3	393.6	372.4	378.6	330.3	153.1	106.7	67	49	81.6	53.1	45.9	32.5	20.6	11.5	4.8
income-statement-row.row.gross-profit	723.3	702.8	893.2	1031.2	949.3	1612.3	1719.2	877.8	658.6	763	870.5	783.2	676.7	469.7	351.1	323	309	155.9	90.8	72.7	60.6	50.4	38.4	27.4
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	166.1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	19.27	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	214.73	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	-0.99	-1	99.2	82.7	75.6	66.4	-10	1	20.2	11.9	32.4	19.3	5.2	11.4	38	10.2	7	9.6	2.3	1	0.5	0.7	0	0.1
income-statement-row.row.operating-expenses	498.87	491.6	711.2	776.1	779.9	1108.5	1050.1	490.9	196.2	186.2	147.1	175.4	158.8	103.7	93.4	83	75.7	62	41.9	40.1	27.4	18.3	16.6	6.7
income-statement-row.row.cost-and-expenses	737.77	797.1	868.2	959.7	943.3	1525.9	1498.4	855.2	547.4	579.8	519.5	554	489.1	256.8	200.1	150	124.7	143.6	95.1	86	59.9	38.9	16.6	6.7
income-statement-row.row.interest-income	14.77	14.2	15.2	16.8	10.5	26.5	21.9	19.3	18.1	20.3	21.7	12.9	10.8	9	7.3	0	4.8	2.2	3.5	4.6	1.2	0.1	0	0
income-statement-row.row.interest-expense	0	0.1	0.1	0.2	0.4	0.1	20.8	18.3	18	0	0	0	0	0	0	-6.8	0	0	0	0	0.1	0	0	0.1
income-statement-row.row.selling-and-marketing-expenses	214.73	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	53.63	241.5	-4	0.3	-0.1	0	2.6	235.7	65	92	89	65.9	42.5	238.5	61.8	33	2.7	55.2	7.7	4.9	1.5	-0.1	0	-0.1
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	-0.99	-1	99.2	82.7	75.6	66.4	-10	1	20.2	11.9	32.4	19.3	5.2	11.4	38	10.2	7	9.6	2.3	1	0.5	0.7	0	0.1
income-statement-row.row.total-operating-expenses	53.63	241.5	-4	0.3	-0.1	0	2.6	235.7	65	92	89	65.9	42.5	238.5	61.8	33	2.7	55.2	7.7	4.9	1.5	-0.1	0	-0.1
income-statement-row.row.interest-expense	0	0.1	0.1	0.2	0.4	0.1	20.8	18.3	18	0	0	0	0	0	0	-6.8	0	0	0	0	0.1	0	0	0.1
income-statement-row.row.depreciation-and-amortization	52.83	145.7	161	134.8	62.3	81.6	55.8	37.5	33.6	32.7	30.7	22.5	20.3	17.6	13.7	12.3	11.9	9.9	7.4	10	9.1	8	-38.4	0.1
income-statement-row.row.ebitda-caps	348.88	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	239.31	211.1	263.3	457.5	412.9	560.9	681.6	621.6	507.2	656.8	780.5	654.6	555.1	593	281.6	262.9	229	139.5	57.4	38.4	35.3	33.2	21.8	20.6
income-statement-row.row.income-before-tax	292.94	452.6	259.4	457.8	412.8	560.9	671.6	622.6	527.4	668.7	812.4	673.7	560.3	604.5	319.6	273	236	149.1	58.2	38.4	35.3	33	21.8	20.6
income-statement-row.row.income-tax-expense	22.25	49.9	31	36.5	51.3	81.4	108.3	93.9	80	91.5	111.4	101.7	80.4	80.1	43.2	29.3	17.6	14.3	7.8	4.6	3.3	1.8	2.6	1.7
income-statement-row.row.net-income	284.9	416.7	234.4	425.9	364.7	486.8	571.4	533.6	452.1	575	695.1	577.4	481	523.3	272.7	244.1	217.9	134.8	50.3	33.8	32	31.2	19.3	18.9